Hepta Reveals Blood-Based Epigenetic Signatures of GLP-1 Response, Enabling Precision Medicine in Obesity and MASH

Key Takeaways

• cfDNA methylation predicts semaglutide responders before first dose
• One‑year treatment shows distinct epigenetic shifts absent in placebo
• LiquidTransformer AI reads millions of cfDNA fragments for analysis
• Pathway signatures link to lipid metabolism, incretin signaling, fibrosis
• Tool could shift GLP‑1 prescribing to biology‑guided decisions

Pulse Analysis

The explosion of GLP‑1 agonists such as semaglutide has transformed obesity and metabolic‑associated steatohepatitis (MASH) treatment, yet clinicians lack a scalable way to know who will benefit. Traditional weight‑loss metrics are only observable after weeks of therapy, leading to costly trial‑and‑error cycles. A blood‑based biomarker that predicts response before exposure would not only improve patient outcomes but also optimize healthcare resource allocation, especially as payer scrutiny intensifies.

Hepta’s new assay leverages cell‑free DNA methylation patterns captured from a routine plasma draw. In the SAMARA real‑world study, baseline methylation signatures accurately separated patients who achieved ≥10% weight loss from non‑responders, with statistical significance (p < 0.01). Over roughly one year, participants on semaglutide exhibited longitudinal epigenetic changes across pathways governing lipid metabolism, incretin signaling, and anti‑fibrotic remodeling—changes absent in the placebo group. The data were processed by the LiquidTransformer, an attention‑based AI model that interrogates hundreds of millions of cfDNA fragments, delivering a high‑resolution view of disease biology.

Beyond semaglutide, the platform promises a broader impact on metabolic therapeutics. By providing a non‑invasive, real‑time readout of drug‑induced biological shifts, pharmaceutical developers can refine trial designs, and clinicians can tailor therapy selection across GLP‑1 analogues, dual‑agonists, and emerging agents. As the market for weight‑loss drugs expands, tools that convert blood‑based epigenetic signals into actionable insights will become essential for delivering precision medicine at scale. Hepta’s partnership discussions with major pharma underscore the commercial relevance of this approach.